Science 37
Science 37 is a United States clinical research company focused on decentralized and site-less clinical trials.
Last updated August 24, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Science 37 is a clinical research company that developed technology and operational services for decentralized clinical trials. Its model was designed to reduce the dependence of clinical studies on conventional research sites by allowing patients to participate remotely or in their homes. The company combined digital recruitment, electronic consent, telemedicine-style video interactions, remote data collection, mobile nursing visits, and delivery of study medication or other materials to participants. The company was founded in 2014 by Noah Craft and Belinda Tan while working out of LA BioMed at Harbor-UCLA Medical Center. Its core technology was the Network Oriented Research Assistant platform, commonly called NORA. NORA was intended to coordinate interactions among study participants, investigators, clinical staff, and sponsors. Features described for the platform included video communication, digital self-photography, electronic consent, participant data collection, recruitment support, scheduling, questionnaires, in-home visits by mobile nurses, and doorstep delivery of investigational medicines. Science 37 positioned this approach as a way to broaden access to clinical trials and make participation more convenient for people who could not easily travel to traditional research sites. The company’s services were relevant to pharmaceutical and biotechnology sponsors seeking to recruit participants, operate remote trial activities, and collect data outside conventional hospitals or research centers. Its work therefore sat at the intersection of contract research services, clinical-trial technology, telehealth-enabled care coordination, and patient recruitment. The company began working with Genentech on participant recruitment in 2015. In 2017, it completed a site-less study for AOBiome Therapeutics that was described as the first interventional, randomized, placebo-controlled trial completed virtually. Science 37 also worked on or planned decentralized studies with Sanofi, Otsuka Pharmaceutical, and Novartis. Its relationship with Novartis included an early-stage investment, and the companies explored studies involving acne, cluster headaches, and fatty liver disease. Science 37 raised several private financing rounds as it expanded. It received a $6.5 million initial investment in 2015, followed by a $31 million round in 2016 and a $29 million round in 2017. It reported a $35 million Series D round in March 2019 and a further oversubscribed $40 million financing round in August 2020 led by Lux Capital, Redmile Group, and PPD. In November 2019, David Coman became chief executive officer. In May 2021, the company announced plans to become publicly listed through a proposed merger with LifeSci Acquisition II Corp.; the provided reference material does not establish that the transaction was completed. In March 2024, Science 37 was acquired by eMed, LLC. The acquisition marked a change in ownership and placed the Science 37 business within eMed’s broader digital-health and clinical-research activities. Publicly available information in the supplied material does not establish the company’s post-acquisition operating structure, current leadership, headquarters, or whether the Science 37 name continues as an independent operating brand.
History
Science 37 was established in 2014 by Noah Craft and Belinda Tan while the founders were working at LA BioMed at Harbor-UCLA Medical Center. From the outset, the company focused on changing how clinical research was organized. Rather than treating the hospital or investigator site as the sole center of a study, Science 37 sought to coordinate research activities around the participant, using digital communication and services delivered in the home. The company’s principal technology was the Network Oriented Research Assistant platform, known as NORA. The platform combined video chat, electronic consent, digital self-photography, data collection, recruitment support, and scheduling. These tools were paired with operational services such as remote questionnaires, mobile nurse visits, and delivery of study medicines to participants’ homes. Together, the technology and services supported what Science 37 called site-less trials, in which a study could be conducted without relying exclusively on a network of traditional physical research locations. Science 37 began building relationships with pharmaceutical and biotechnology companies early in its development. In 2015, it worked with Genentech on recruiting clinical-trial participants. In 2017, the company completed a virtual study for AOBiome Therapeutics. The study was described as an interventional, randomized, placebo-controlled trial and became an important example of the company’s decentralized approach. During the same period, Science 37 began planning site-less trials for Sanofi and Otsuka Pharmaceutical. Novartis became another important partner. In 2018, Science 37 worked with Novartis on planning several site-less clinical trials. Novartis had also made an early-stage investment in Science 37 and was reported to own 10 percent of the company. The companies were involved in studies related to acne, cluster headaches, and fatty liver disease. These relationships helped establish Science 37 as a specialist provider for sponsors testing decentralized methods in different therapeutic areas. The company financed its expansion through private investment. Its initial 2015 funding round totaled $6.5 million and was co-led by Lux Capital and dRx Capital. A 2016 round produced $31 million in funding, followed by a $29 million round in 2017. In March 2019, Science 37 secured a further $35 million Series D financing. In November of that year, the company announced that David Coman would become chief executive officer, representing a leadership transition as the business moved toward larger-scale commercial growth. In August 2020, Science 37 closed an oversubscribed $40 million financing round led by Lux Capital, Redmile Group, and PPD. Other named participants included Novartis, Amgen, Sanofi Ventures, GV, Glynn Capital, LifeSci Ventures, and Mubadala Ventures. The financing reflected continuing investor and industry interest in decentralized clinical-trial infrastructure, particularly as remote research practices became more prominent. In May 2021, Science 37 announced a plan to become a publicly listed company through a merger with LifeSci Acquisition II Corp. The supplied reference material does not establish that the proposed transaction closed, and no ticker or completed listing should therefore be assigned. In March 2024, Science 37 was acquired by eMed, LLC. The acquisition is the latest ownership event identified in the supplied sources. Details about the company’s current legal structure, leadership, headquarters, operating markets, and brand status after the acquisition remain unclear.
- 2024
Acquisition by eMed
[1]eMed, LLC acquired Science 37 in March 2024.
- 2021
Proposed public listing
[1]Science 37 announced a proposed merger with LifeSci Acquisition II Corp. intended to make the company publicly listed; completion is not established in the supplied sources.
- 2020
Oversubscribed $40 million financing
[1]Science 37 closed an oversubscribed $40 million financing round led by Lux Capital, Redmile Group, and PPD.
- 2019
Series D financing and chief executive transition
[1]The company reported a $35 million Series D round and later announced David Coman as chief executive officer.
- 2018
Novartis site-less trial planning
[1]Science 37 partnered with Novartis to plan several site-less clinical trials.
- 2017
Virtual site-less trial completed
[1]Science 37 completed a virtual interventional, randomized, placebo-controlled trial for AOBiome Therapeutics and raised a further $29 million.
- 2016
Second financing round
[1]A subsequent financing round brought in $31 million.
- 2015
Initial financing and Genentech collaboration
[1]Science 37 received a $6.5 million initial investment and began working with Genentech on clinical-trial participant recruitment.
- 2014
Science 37 is founded
[1]Noah Craft and Belinda Tan founded Science 37 while working out of LA BioMed at Harbor-UCLA Medical Center.
Products and positioning
A technology-enabled clinical research partner that helps pharmaceutical and biotechnology sponsors conduct decentralized trials with fewer conventional site visits and greater use of remote participation.
Clinical-trial technology platform
NORA platform
The Network Oriented Research Assistant platform was Science 37’s core digital system for coordinating decentralized clinical research. It incorporated video communication, electronic consent, digital self-photography, data collection, participant recruitment assistance, and scheduling. NORA supported interactions between participants, researchers, and mobile clinical personnel and helped organize activities that could occur outside traditional research sites.
Clinical research service
Site-less clinical trials
Science 37’s site-less trial offering was designed to conduct clinical studies with limited dependence on conventional physical research locations. Participants could complete digital questionnaires and consent procedures remotely, communicate through video, receive mobile nurse visits, and obtain study medicines at home. The model was intended to improve convenience and extend recruitment beyond the geographic catchment areas of individual trial sites.
Clinical research service
Participant recruitment and engagement
Science 37 provided capabilities for finding, contacting, scheduling, and supporting potential clinical-trial participants. These capabilities were used in work with sponsors including Genentech and were integrated with the company’s broader decentralized-trial processes.
Clinical research service
Remote and in-home trial operations
The company coordinated remote study activities such as questionnaires, teleconferenced interactions, mobile nurse visits, digital data collection, and doorstep delivery of study medication. These services supported clinical-trial participation from a patient’s home or another location away from a conventional research center.
Brand decisions
2024
Acquisition by eMedM&ABackground
Science 37 continued operating in decentralized clinical research before its ownership changed in 2024.
Action taken
eMed, LLC acquired Science 37 in March 2024.
Aftermath
Science 37 became part of eMed. The supplied sources do not specify the post-acquisition brand, management, or operating structure.
2021
Proposed merger intended to create a public listingStrategyBackground
Science 37 announced plans to access public markets as decentralized clinical research attracted greater attention.
Action taken
The company announced a proposed merger with LifeSci Acquisition II Corp.
Aftermath
The supplied reference material does not confirm whether the proposed merger closed, so no completed listing or ticker is assigned.
2017
Completion of a virtual randomized clinical trialProduct launchBackground
Science 37 was developing its site-less clinical-trial model and worked with AOBiome Therapeutics on a fully virtual interventional, randomized, placebo-controlled study.
Action taken
The company completed the study using its decentralized operating approach rather than relying exclusively on conventional physical research sites.
Aftermath
The trial became a prominent example of Science 37’s approach and was described as the first interventional, randomized, placebo-controlled trial completed virtually.
Recent events
Reported
Science 37 launches electronic health record integration[2]
Science 37 launched an electronic health record integration feature for its decentralized clinical trial technology platform. It enables patients to authorize and share health records in real time for participation in decentralized clinical trials.
Reported
Science 37 and AiCure team up on virtual clinical trials[3]
Science 37 and AiCure teamed up to provide telemedicine tools for virtual clinical trials, starting with support for a 150-person trial of a treatment for major depressive disorder.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/science-37 · Editorial policy · How profiles are compiled